Rami S. Komrokji - Concepedia

Author

Rami S. Komrokji

Also Known As

Bewersdorf, Jan Philipp, Gastone Castellani, Jesus Diaz Vera, Martin Jädersten, R Komrokji, R S Komrokji, R. Komrokji, R. S. Komrokji, R.S. Komrokji, RAMI KOMROKJI

1.5K

Publications

18.4K

Citations

H-Index

124

Concepts

All Affiliations

Moffitt Cancer Center Cleveland Clinic The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute Cornell University

About

Rami S. Komrokji is an author at Moffitt Cancer Center specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	102	5.2K
2	Health Sciences	22	35	1.9K
3	Public Health	5	5	264
4	Engineering	3	3	77
5	Social Sciences	1	1	26

Rami S. Komrokji

236

Publications

14.1K

Citations

H-Index

Page 1

	Year	Citations
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, New England Journal of Medicine	2020	519
Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero, Journal of Clinical Oncology	2021	436
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype Ashley A. Basiorka, Kathy L. McGraw, Erika A. Eksioglu, Blood	2016	337
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML Jeffrey E. Lancet, Jörge E. Cortes, Donna E. Hogge, Blood	2014	334
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis Francesco Passamonti, Toni Giorgino, Barbara Mora, Leukemia Hematological MalignancyThrombosisTranslational MedicineOncologyMalignant Blood Disorder	2017	323
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study Nancy Gillis, Markus Ball, Qing Zhang, The Lancet Oncology Hematological MalignancyOncologyBone Marrow FailureElderly PatientsMalignant Blood Disorder	2016	307
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali, Journal of the National Comprehensive Cancer Network Hematological MalignancyOncologyDiagnostic ClassificationBone Marrow FailureDiagnostic Criteria	2016	293
Myelodysplastic Syndromes P Greenberg, Eyal C. Attar, John M. Bennett, Journal of the National Comprehensive Cancer Network	2011	289
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) Thomas Cluzeau, Marie Sébert, Ramy Rahmé, Journal of Clinical Oncology	2021	256
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups Detlef Haase, Kristen E. Stevenson, Donna Neuberg, Leukemia	2019	252

Page 1